CureVac (NASDAQ:CVAC) stock price is going up again, this time on phase 2 news. German based company has started the second phase of testing its vaccine candidate. The first participant in the phase 2a study had been vaccinated, it is announced Tuesday evening. The study is running in Peru and Panama with 690 healthy participants.
First data are expected in the fourth quarter. After that, the company plans to start the crucial phase 3 study with up to 30,000 participants.
Jean Stéphenne, on CureVac’s board of directors, recently said the vaccine could be available in six to nine months. After the Mainz company BioNTech, the company was the second German company to receive approval for a clinical study. The vaccine is based on the messenger molecule mRNA and stimulates the production of a virus protein in the body. This triggers an immune response that is supposed to protect people from the virus. The vaccine study started in mid-June.